COMMUNIQUÉS West-GlobeNewswire

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
17/04/2024
RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted approval for oral, once- [...]
Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU Plan
17/04/2024
Tokyo, Japan and Cambridge, UK, 17 April 2024 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that it has decided to issue new shares (“the Share [...]
Q1 2024 Revenue and Business Update
17/04/2024
MELBOURNE, Australia, April 17, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended 31 March [...]
Theolytics successfully closes latest financing raising total of £19M ($24.5M) and welcomes Sound Bioventures as new investor
17/04/2024
Oxford, UK April 17th, 2024 . Theolytics, a biotechnology company developing next-generation oncolytic viral therapies, today announced it has successfully closed its latest financing round, raising a total of £19M ($24 [...]
Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules
17/04/2024
Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules Reminyl® is an established CNS brand for the symptomatic treatment of mild to moderately severe dementia of the Alzheimer [...]
Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
17/04/2024
Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through 48 weeks The [...]
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
17/04/2024
Continuous Kesimpta ® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis of the ALITHIOS open- [...]
Idorsia publishes a Financial Status required for an upcoming bondholder meeting
17/04/2024
Ad hoc announcement pursuant to Art. 53 LR Unaudited Financial Status as of March 31, 2024, required for an upcoming bondholder meeting, now available on the company website Bondholder meeting now planned for early May [...]
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
17/04/2024
New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte depleting treatment for [...]
Communiqué de presse : De nouveaux résultats de phase II à 48 semaines relatifs au frexalimab confortent le potentiel d'efficacité élevée et durable dans le traitement de la sclérose en plaques
17/04/2024
De nouveaux résultats de phase II à 48 semaines relatifs au frexalimab confortent le potentiel d'efficacité élevée et durable dans le traitement de la sclérose en plaques Les données montrent que le frexalimab a le [...]
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
17/04/2024
WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR [...]
Health Advocate Applauds Federal Budget 2024 in providing costing on a National Pharmacare Plan; a milestone in universal free access to contraceptives
17/04/2024
OTTAWA, April 16, 2024 (GLOBE NEWSWIRE) -- The Society of Obstetricians and Gynaecologists of Canada (SOGC) applauds the federal government’s announcement of $1.5 billion in funding over five years to support the launch [...]
Les professionnels de la santé des femmes applaudissent le budget fédéral 2024 incluant les coûts pour un Plan national d'assurance-médicaments; une étape importante vers un accès universel et gratuit à toutes les méthodes contraceptives
17/04/2024
OTTAWA, 16 avr. 2024 (GLOBE NEWSWIRE) -- La Société des obstétriciens et gynécologues du Canada (SOGC) applaudit l'annonce du gouvernement fédéral prévoyant 1,5 milliard de dollars sur cinq ans pour soutenir le [...]
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
17/04/2024
SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the closing of its underwritten public offering of 11,916,667 shares of its common stock at a public offering [...]
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
16/04/2024
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the U.S. on or after [...]
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
16/04/2024
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the U.S. on or after [...]
Panbela Announces Transfer to OTCQB Market
16/04/2024
MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical [...]
Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024
16/04/2024
KANSAS CITY, Kan., April 16, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and [...]
INVO Reports Fourth Quarter and Full Year 2023 Financial Results
16/04/2024
SARASOTA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide [...]

Pages